241 related articles for article (PubMed ID: 27696904)
1. Investigational calcium channel blockers for the treatment of hypertension.
Tamargo J; Ruilope LM
Expert Opin Investig Drugs; 2016 Nov; 25(11):1295-1309. PubMed ID: 27696904
[TBL] [Abstract][Full Text] [Related]
2. [New calcium channel blockers for the treatment of hypertension].
Tamargo J
Hipertens Riesgo Vasc; 2017; 34 Suppl 2():5-8. PubMed ID: 29908667
[TBL] [Abstract][Full Text] [Related]
3. Ca2+ channel subtypes and pharmacology in the kidney.
Hayashi K; Wakino S; Sugano N; Ozawa Y; Homma K; Saruta T
Circ Res; 2007 Feb; 100(3):342-53. PubMed ID: 17307972
[TBL] [Abstract][Full Text] [Related]
4. Vascular effects of calcium channel antagonists: new evidence.
Richard S
Drugs; 2005; 65 Suppl 2():1-10. PubMed ID: 16398057
[TBL] [Abstract][Full Text] [Related]
5. Effect of benidipine hydrochloride, a long-acting T-type calcium channel blocker, on blood pressure and renal function in hypertensive patients with diabetes mellitus. Analysis after switching from cilnidipine to benidipine.
Seino H; Miyaguchi S; Yamazaki T; Ota S; Yabe R; Suzuki S
Arzneimittelforschung; 2007; 57(8):526-31. PubMed ID: 17915639
[TBL] [Abstract][Full Text] [Related]
6. Effect of N- and T-type calcium channel blocker on proteinuria, blood pressure and kidney function in hypertensive patients: a meta-analysis.
Thamcharoen N; Susantitaphong P; Wongrakpanich S; Chongsathidkiet P; Tantrachoti P; Pitukweerakul S; Avihingsanon Y; Praditpornsilpa K; Jaber BL; Eiam-Ong S
Hypertens Res; 2015 Dec; 38(12):847-55. PubMed ID: 26134125
[TBL] [Abstract][Full Text] [Related]
7. T-type Ca channel blockade as a determinant of kidney protection.
Hayashi K; Homma K; Wakino S; Tokuyama H; Sugano N; Saruta T; Itoh H
Keio J Med; 2010; 59(3):84-95. PubMed ID: 20881449
[TBL] [Abstract][Full Text] [Related]
8. Calcium channel blockers in cardiovascular pharmacotherapy.
Godfraind T
J Cardiovasc Pharmacol Ther; 2014 Nov; 19(6):501-15. PubMed ID: 24872348
[TBL] [Abstract][Full Text] [Related]
9. Renoprotective effects of the L-/T-type calcium channel blocker benidipine in patients with hypertension.
Tomino Y
Curr Hypertens Rev; 2013 May; 9(2):108-14. PubMed ID: 23971692
[TBL] [Abstract][Full Text] [Related]
10. [Pleiotropic effects of new generation calcium channel blockers on cardiovascular protections].
Ogimoto A; Higaki J
Clin Calcium; 2013 Apr; 23(4):569-74. PubMed ID: 23545747
[TBL] [Abstract][Full Text] [Related]
11. Comparison between the antiproteinuric effects of the calcium channel blockers benidipine and cilnidipine in combination with angiotensin receptor blockers in hypertensive patients with chronic kidney disease.
Abe M; Okada K; Maruyama N; Matsumoto S; Maruyama T; Fujita T; Matsumoto K; Soma M
Expert Opin Investig Drugs; 2010 Sep; 19(9):1027-37. PubMed ID: 20649501
[TBL] [Abstract][Full Text] [Related]
12. L/T-type and L/N-type calcium-channel blockers attenuate cardiac sympathetic nerve activity in patients with hypertension.
Ogura C; Ono K; Miyamoto S; Ikai A; Mitani S; Sugimoto N; Tanaka S; Fujita M
Blood Press; 2012 Dec; 21(6):367-71. PubMed ID: 22747420
[TBL] [Abstract][Full Text] [Related]
13. Renal microcirculation and calcium channel subtypes.
Homma K; Hayashi K; Yamaguchi S; Fujishima S; Hori S; Itoh H
Curr Hypertens Rev; 2013 Aug; 9(3):182-6. PubMed ID: 24479750
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the cardioprotective and renoprotective effects of the L/N-type calcium channel blocker, cilnidipine, in adriamycin-treated spontaneously-hypertensive rats.
Aritomi S; Harada E; Sugino K; Nishimura M; Nakamura T; Takahara A
Clin Exp Pharmacol Physiol; 2015 Apr; 42(4):344-52. PubMed ID: 25582553
[TBL] [Abstract][Full Text] [Related]
15. Questioning the renoprotective role of L-type calcium channel blockers in chronic kidney disease using physiological modeling.
Moore KH; Clemmer JS
Am J Physiol Renal Physiol; 2021 Oct; 321(4):F548-F557. PubMed ID: 34486399
[TBL] [Abstract][Full Text] [Related]
16. L/N-type calcium channel blocker cilnidipine added to renin-angiotensin inhibition improves ambulatory blood pressure profile and suppresses cardiac hypertrophy in hypertension with chronic kidney disease.
Kanaoka T; Tamura K; Wakui H; Ohsawa M; Azushima K; Uneda K; Kobayashi R; Fujikawa T; Tsurumi-Ikeya Y; Maeda A; Yanagi M; Toya Y; Umemura S
Int J Mol Sci; 2013 Aug; 14(8):16866-81. PubMed ID: 23959116
[TBL] [Abstract][Full Text] [Related]
17. L/N-type calcium channel blocker cilnidipine ameliorates proteinuria and inhibits the renal renin-angiotensin-aldosterone system in deoxycorticosterone acetate-salt hypertensive rats.
Toba H; Yoshida M; Tojo C; Nakano A; Oshima Y; Kojima Y; Noda K; Wang J; Kobara M; Nakata T
Hypertens Res; 2011 Apr; 34(4):521-9. PubMed ID: 21270815
[TBL] [Abstract][Full Text] [Related]
18. Functional and pharmacological consequences of the distribution of voltage-gated calcium channels in the renal blood vessels.
Hansen PB
Acta Physiol (Oxf); 2013 Apr; 207(4):690-9. PubMed ID: 23351056
[TBL] [Abstract][Full Text] [Related]
19. Role of antihypertensive therapy with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers in combination with calcium channel blockers for stroke prevention.
Talbert RL
J Am Pharm Assoc (2003); 2010; 50(5):e116-25. PubMed ID: 20833609
[TBL] [Abstract][Full Text] [Related]
20. Effects of T-type calcium channel blockers on renal function and aldosterone in patients with hypertension: a systematic review and meta-analysis.
Li X; Yang MS
PLoS One; 2014; 9(10):e109834. PubMed ID: 25330103
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
